tirzepatide 3 month jump start program Jumpstart Tirzepatide dosage chart for weight

Neuroscience 113 (2), 421434 (2002)

Sampath Kumar

Tagliari, B

Figure 4 illustrates the potential pathways of the function of GLP-1RAs against multiple diseases

Coskun and Urva (2022, pharmacological description) describe the engineering: modified sequence derived from native GIP, Aib2 and Aib13 substitutions resisting DPP-4, and a C20 diacid fatty-acyl chain grafted to a lysine via a gamma-glutamate linker to extend half-life to approximately 6 days

Positive results from the SELECT trial and subsequent FDA approval have increased awareness and acceptance of Wegovy as a cardiovascular risk reduction therapy, leading to greater adoption by patients and healthcare providers